FdaApplication
NDA 218944
Identifiers
- fda_app_no: NDA218944
Properties
| Property | Value |
|---|---|
| applicant_name | SYNDAX PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2024-11-15 |
Revenue by product
REVUFORJ
| Period | Revenue |
|---|---|
| Q3 2025 | $32.0M |
| Q1 2025 | $20.0M† |
| Q3 2024 | $12.5M† |
| Q2 2024 | $3.5M† |
| Q1 2024 | $0.0M† |
| Q4 2023 | $0.0M† |
| Q3 2023 | $0.0M† |
| Q2 2023 | $0.0M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| REVUFORJ | REVUMENIB CITRATE | EQ 110MG BASE | TABLET;ORAL |
| REVUFORJ | REVUMENIB CITRATE | EQ 160MG BASE | TABLET;ORAL |
| REVUFORJ | REVUMENIB CITRATE | EQ 25MG BASE | TABLET;ORAL |
3 products